October 1, 2025: Supriya Lifescience Limited has announced that its Ambernath facility has successfully cleared the World Health Organisation’s (WHO) Good Manufacturing Practice (GMP) audit. Following the inspection held on September 2, 2025, the WHO has officially granted the company WHO-GMP certification for inhalation dosages on September 30, 2025.
With this recognition, Supriya Lifescience is now authorized to carry out large-scale production and global distribution of its inhalation dosage products in regulated and eligible markets across the world.
In its exchange filing, the company stated that the certification will not have any immediate material impact on its financials or ongoing operations. Existing supplies from the facility will continue without disruption. However, the approval strengthens Supriya Lifescience’s regulatory credentials and opens new doors for international market expansion.
This certification also reinforces India’s growing presence in the global pharmaceutical industry, with domestic manufacturers increasingly meeting stringent international compliance standards.
Company Statement:
Prachi Sathe, Company Secretary & Compliance Officer, said: “The WHO-GMP certification of our Ambernath unit reflects our strong commitment to world-class manufacturing practices and quality assurance. This milestone positions us well for future growth in international markets.”
Leave a Reply